Nicotinamide Riboside ( DrugBank: Nicotinamide, Nicotinamide riboside )

---

5 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
6	Parkinson disease	3
18	Spinocerebellar degeneration	1
97	Ulcerative colitis	1
191	Werner syndrome	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04562831 (ClinicalTrials.gov)	October 7, 2020	10/9/2020	The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.	A Randomized Placebo-controlled Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Study	Amyotrophic Lateral Sclerosis	Dietary Supplement: EH301 (Nicotinamide Riboside/Pterostilbene)	Haukeland University Hospital	Elysium Health	Recruiting	35 Years	N/A	All	380	N/A	Norway

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05589766 (ClinicalTrials.gov)	November 28, 2022	13/10/2022	N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	N-DOSE: A Dose Optimization Trial of Nicotinamide Riboside in Parkinson's Disease	Parkinson Disease	Dietary Supplement: Nicotinamide Riboside;Other: Placebo	Haukeland University Hospital	NULL	Recruiting	40 Months	100 Years	All	80	N/A	Norway
2	NCT03568968 (ClinicalTrials.gov)	May 15, 2020	14/6/2018	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease	A Randomized Controlled Trial of Nicotinamide Supplementation in Early Parkinson's Disease: the NOPARK Study	Parkinson Disease	Dietary Supplement: Nicotinamide Riboside;Drug: Placebo	Haukeland University Hospital	NULL	Recruiting	18 Years	N/A	All	400	N/A	Norway
3	NCT03816020 (ClinicalTrials.gov)	March 9, 2019	7/12/2018	NAD-supplementation in Drug naïve Parkinson's Disease	NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease	Parkinson Disease;Neurodegenerative Diseases	Dietary Supplement: Nicotinamide Riboside;Other: Placebo	Haukeland University Hospital	NULL	Completed	18 Years	N/A	All	30	N/A	Norway

18. Spinocerebellar degeneration

---

Clinical trials : 76 /  Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04192136 (ClinicalTrials.gov)	September 3, 2020	6/12/2019	NAD+ and Exercise in FA	NAD+ Precursor Supplementation With Exercise Training to Increase Aerobic Capacity in Friedreich's Ataxia	Friedreich Ataxia 1	Dietary Supplement: Nicotinamide Riboside;Dietary Supplement: Placebo;Other: Exercise Intervention	Children's Hospital of Philadelphia	National Heart, Lung, and Blood Institute (NHLBI)	Recruiting	10 Years	40 Years	All	72	N/A	United States

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05561738 (ClinicalTrials.gov)	January 1, 2023	13/9/2022	Nicotinamide Riboside in Ulcerative Colitis	Nicotinamide Riboside in Ulcerative Colitis	Ulcerative Colitis	Dietary Supplement: Nicotinamide Riboside Chloride;Dietary Supplement: Placebo;Other: Standard of Care	University of Pittsburgh	Crohn's and Colitis Foundation	Not yet recruiting	N/A	18 Years	All	40	N/A	United States

191. Werner syndrome

---

Clinical trials : 3 /  Drugs : 4 - (DrugBank : 3) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190141	19/03/2021	27/11/2019	Cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome	Prospective, single-center, cross-over trial to verify safety and effectiveness of nicotinamide riboside for patients with Werner syndrome - EMPOWER	Werner syndrome Werner syndrome;C16.320.925 / C18.452.284.960	Subjects ingest oral capsules of NR (nicotinamide riboside) once daily (total daily dose: nicotinamide riboside 1000 mg).	Yokote Koutaro	NULL	Recruiting	>= 20age old	Not applicable	Both	30	Phase 1-2	Japan

Back to top